Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPELLER: 64Cu-SAR-bisPSMA PET Imaging in Prostate Cancer
NCT04839367Phase 1Completed
- Sponsor
- Clarity Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Oct 2022
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of 64Cu-SAR-bisPSMA in prostate cancer (PCa) (3 cohorts), sponsored by Clarity Pharmaceuticals. Primary endpoints: Safety and tolerability of 64Cu-SAR-bisPSMA at 11 weeks and Efficacy of 64Cu-SAR-bisPSMA in the Detection of Primary Prostate Cancer Compared to Histopathology at 11 weeks. Started Jul 2021; status: completed.
02
Drugs
64Cu-SAR-bisPSMA
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04839367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839367.